XRAY Trading Below Director's Recent Buy Price

DENTSPLY SIRONA Inc's Director, Gregory T. Lucier, purchased 15,142 shares of XRAY on March 3rd at $16.51 per share, signaling potential confidence in the company's prospects; however, XRAY shares have since traded as low as $15.74, 4.7% below Lucier's purchase price, and are currently trading off about 0.7% on the day, with Lucier's total return currently down 3.7% when including dividends.

Analysis

Insider buying activity at DENTSPLY SIRONA Inc. (XRAY) involved Director Gregory T. Lucier purchasing 15,142 shares on March 3 for $249,994.42, at a cost of $16.51 per share. This action is typically interpreted on Wall Street as a signal of strong confidence in the company's prospects. However, XRAY shares have since traded at a discount, with a low of $15.74, 4.7% cheaper than Lucier's entry point, and were recently trading around $15.99, down approximately 0.7% on the day. Consequently, even after collecting $0.16 per share in dividends, Lucier's investment is currently showing a 3.7% loss on a total return basis. The stock's 52-week range is $12.16 to $27.95, and DENTSPLY SIRONA offers an annualized dividend of $0.64 per share, yielding approximately 4.0%. While insider buying is a noteworthy event, the subsequent price action and the director's current unrealized loss warrant careful consideration, aligning with the speculative tone often associated with interpreting such signals.

Key Decisions for Investors

• Investors could view the director's substantial purchase as a bullish long-term indicator, particularly as current share prices offer a 4.7% discount to the insider's entry point.
• The approximately 4.0% annualized dividend yield provides a tangible return component that may appeal to income-focused investors or those willing to hold while monitoring for price recovery toward the insider's purchase level.
• Acknowledge the current 3.7% unrealized loss on the director's investment; while insider buying is generally positive, the immediate market disagreement suggests monitoring for further confirmation or divergence is prudent.